WORLD PEPTIDEFOUNDATION
← Master Registry

Published peptide research references

Bremelanotide

Governed registry record

52 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.

Open the peptide evidence profile →

Approved source records

  1. (020) Real-World Use of Bremelanotide in One Sexual Medicine Clinic Treating Women with Hypoactive Sexual Desire Disorder

    DOI: 10.1093/jsxmed/qdad061.020

    Source identity and connection checked by Codex (AI).

  2. (033) Examining the Neuroanatomical Basis of Bremelanotide, a Drug for Low Sexual Desire in Women

    DOI: 10.1093/jsxmed/qdad061.033

    Source identity and connection checked by Codex (AI).

  3. (035) USE OF BREMELANOTIDE IN MEN WITH SEXUAL DYSFUNCTION AT A SEXUAL MEDICINE CLINIC

    DOI: 10.1093/jsxmed/qdae161.029

    Source identity and connection checked by Codex (AI).

  4. (060) Comparison of Prescribing and Google Trends Between Bremelanotide (Vyleesi®) and Flibanserin (Addyi®) for Female Hypoactive Sexual Desire Disorder

    DOI: 10.1093/jsxmed/qdag063.057

    Source identity and connection checked by Codex (AI).

  5. (122) POSITIVE EFFECTS OF BREMELANOTIDE ON FEMALE SEXUAL AROUSAL AND ORGASM IN PREMENOPAUSAL WOMEN WITH HSDD: FSFI DATA FROM THE RECONNECT TRIALS

    DOI: 10.1093/jsxmed/qdaf068.108

    Source identity and connection checked by Codex (AI).

  6. (227) Use of the CNS Agent Bremelanotide in Men with Sexual Dysfunction: Results from a Sexual Medicine Clinic

    DOI: 10.1093/jsxmed/qdae001.217

    Source identity and connection checked by Codex (AI).

  7. (235) Use of Bremelanotide (Vyleesi) in Men with Sexual Dysfunctions

    DOI: 10.1093/jsxmed/qdae001.225

    Source identity and connection checked by Codex (AI).

  8. (396) Comparative Analysis of Flibanserin, Bremelanotide, and Testosterone Therapy for Female Sexual Desire: Mechanism, Efficacy, and Clinical Considerations

    DOI: 10.1093/jsxmed/qdaf320.390

    Source identity and connection checked by Codex (AI).

  9. Author response for "Effect of bremelanotide on body weight of obese women: data from two phase 1 randomized controlled trials"

    DOI: 10.1111/dom.14672/v2/response1

    Source identity and connection checked by Codex (AI).

  10. BREMELANOTIDE

    DOI: 10.1017/9781009464772.015

    Source identity and connection checked by Codex (AI).

  11. Bremelanotide (Vyleesi) A Melanocortin Receptor Agonist for Treating Female Hypoactive Sexual Desire Disorder

    DOI: 10.1002/9781394225156.ch16

    Source identity and connection checked by Codex (AI).

  12. Bremelanotide for Treatment of Female Hypoactive Sexual Desire.

    DOI: 10.3390/neurolint14010006PMID: 35076581

    Source identity and connection checked by Codex (AI).

  13. Bremelanotide for hypoactive sexual desire syndrome in pre-menopausal women

    DOI: 10.1016/j.nsa.2023.103648

    Source identity and connection checked by Codex (AI).

  14. Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling.

    DOI: 10.1039/d6ay01098aPMID: 42485063

    Source identity and connection checked by Codex (AI).

  15. Cryo-EM structure of bremelanotide-MC4R-Gs_Nb35 complex

    DOI: 10.2210/pdb7f55/pdb

    Source identity and connection checked by Codex (AI).

  16. Decision letter for "Effect of bremelanotide on body weight of obese women: data from two phase 1 randomized controlled trials"

    DOI: 10.1111/dom.14672/v2/decision1

    Source identity and connection checked by Codex (AI).

  17. Expression of Concern: Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study.

    DOI: 10.1097/ju.0000000000003117PMID: 36626345

    Source identity and connection checked by Codex (AI).

  18. G-423 Efficacy of Bremelanotide (BMT) to Stabilize Podocyte Function and Reduce Proteinuria in Adults with Type II Diabetic Nephropathy: Results from a Phase IIb, Open-Label Study

    DOI: 10.1053/j.ajkd.2025.02.424

    Source identity and connection checked by Codex (AI).

  19. PD52-03 USE OF THE CNS AGENT BREMELANOTIDE IN MEN WITH SEXUAL DYSFUNCTION: RESULTS FROM A SEXUAL MEDICINE CLINIC

    DOI: 10.1097/01.ju.0001009412.04863.1b.03

    Source identity and connection checked by Codex (AI).

  20. Review for "Effect of bremelanotide on body weight of obese women: data from two phase 1 randomized controlled trials"

    DOI: 10.1111/dom.14672/v2/review1

    Source identity and connection checked by Codex (AI).

  21. Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men?

    DOI: 10.1097/jcp.0000000000002179PMID: 41960633

    Source identity and connection checked by Codex (AI).

  22. TIRZEPATIDE, ELAMIPRETIDE (SS-31), TESAMORELIN AND BREMELANOTIDE: MECHANISTIC FOUNDATIONS, CLINICAL EVIDENCE AND THERAPEUTIC APPLICATIONS IN METABOLIC, MITOCHONDRIAL AND NEUROENDOCRINE CONTEXTS

    DOI: 10.65671/g269y606

    Source identity and connection checked by Codex (AI).

  23. Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder.

    2025

    DOI: 10.1016/j.neuropharm.2025.110299PMID: 39793696

  24. Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells <i>via</i> Suppression of Survivin Expression.

    2024

    DOI: 10.21873/anticanres.17214PMID: 39197897

  25. Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder.

    2024

    DOI: 10.1080/00224499.2023.2175192PMID: 36809187

  26. An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder.

    2023

    DOI: 10.1080/14656566.2022.2132144PMID: 36242769

  27. Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials.

    2022

    DOI: 10.1111/dom.14672PMID: 35170192

  28. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.

    2022

    DOI: 10.1089/jwh.2021.0225PMID: 35230162

  29. Safety Profile of Bremelanotide Across the Clinical Development Program.

    2022

    DOI: 10.1089/jwh.2021.0191PMID: 35147466

  30. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women.

    2022

    DOI: 10.1017/s109285292100002xPMID: 33455598

  31. Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent.

    2021

    DOI: 10.1136/dtb.2021.000020PMID: 34642243

  32. Failure of a Meta-analysis: A Commentary on Glen Spielmans's "Re-Analyzing Phase III Bremelanotide Trials for 'Hypoactive Sexual Desire Disorder in Women'".

    2021

    DOI: 10.1080/00224499.2021.1902926PMID: 33835907

  33. LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs.

    2021

    DOI: 10.1002/dta.2986PMID: 33245851

  34. Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women.

    2021

    DOI: 10.1080/00224499.2021.1885601PMID: 33678061

  35. The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.

    2021

    DOI: 10.1089/jwh.2020.8460PMID: 33538638

  36. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder.

    2020

    DOI: 10.1177/1060028019899152PMID: 31893927

  37. Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics.

    2020

    DOI: 10.1016/j.jpba.2020.113276PMID: 32353679

  38. Bremelanotide (Vyleesi) for hypoactive sexual desire disorder.

    2019

    PMID: 31381550

  39. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.

    2019

    DOI: 10.1097/aog.0000000000003500PMID: 31599840

  40. Bremelanotide: First Approval.

    2019

    DOI: 10.1007/s40265-019-01187-wPMID: 31429064

  41. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.

    2019

    DOI: 10.1097/aog.0000000000003514PMID: 31599847

  42. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.

    2019

    DOI: 10.1016/j.jsxm.2019.05.012PMID: 31277966

  43. Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants.

    2017

    DOI: 10.1016/j.clinthera.2017.01.018PMID: 28189361

  44. Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide.

    2017

    DOI: 10.1097/hjh.0000000000001221PMID: 27977473

  45. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.

    2016

    DOI: 10.2217/whe-2016-0018PMID: 27181790

  46. Re: Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial.

    2016

    DOI: 10.1016/j.juro.2016.08.063PMID: 27751477

  47. Bremelanotide.

    2012

    PMID: 34436837

  48. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.

    2008

    DOI: 10.1016/j.juro.2007.10.063PMID: 18206919

  49. Bremelanotide: an overview of preclinical CNS effects on female sexual function.

    2007

    DOI: 10.1111/j.1743-6109.2007.00610.xPMID: 17958619

  50. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.

    2006

    DOI: 10.1111/j.1743-6109.2006.00268.xPMID: 16839319

  51. Bremelanotide.

    2006

    PMID: 31369224

  52. PT-141 Palatin.

    2004

    PMID: 15134289